Key result
BNT162b2 vaccination in adolescents linked to rare myocarditis/pericarditis, peaking at ~16 per 100,000 in older males.
Why the study?
The risk of myocarditis or pericarditis after COVID-19 mRNA vaccines varies by age, sex, and interdose interval, motivating an evaluation of the incidence and clinical features of these events after BNT162b2 vaccination in adolescents.
What is the incidence and clinical profile of myocarditis or pericarditis after BNT162b2 vaccination among adolescents aged 12 to 17 years, and how does it vary by age, sex, dose number, and interdose interval?
Cohort (n=77)
Yes
What is the incidence and clinical profile of myocarditis or pericarditis after BNT162b2 vaccination among adolescents aged 12 to 17 years, and how does it vary by age, sex, dose number, and interdose interval?
Myocarditis and pericarditis following BNT162b2 vaccination in adolescents are very rare and generally mild (mostly managed with NSAIDs alone), though incidence is highest in 16- to 17-year-old males after dose 2 and with shorter (≤30-day) interdose intervals.
Answers are grounded in this paper and cite their sources.
Rare myocarditis association warrants targeted post-vaccination surveillance in adolescent males; leaves open optimal dosing intervals and long-term outcomes.
Importance: The risk of myocarditis or pericarditis after COVID-19 messenger RNA vaccines varies by age and sex, and there is some evidence to suggest increasing risk with shorter intervals between dose 1 and 2 (ie, interdose interval). Objective: To estimate the incidence of reported myocarditis or pericarditis after BNT162b2 vaccine among adolescents and to describe the clinical information associated with these events. Design, Setting, and Participants: This was a population-based cohort study using passive vaccine safety surveillance data linked to the provincial COVID-19 vaccine registry. Included in the study were all adolescents aged 12 to 17 years in Ontario, Canada, who received 1 or more doses of BNT162b2 vaccine between December 14, 2020, and November 21, 2021, and reported an episode of myocarditis or pericarditis. Data were analyzed from December 15, 2021, to April 22, 2022. Exposure: Receipt of BNT162b2 (Comirnaty [Pfizer-BioNTech]) vaccine. Main Outcomes and Measure: Reported incidence of myocarditis or pericarditis meeting level 1 to 3 of the Brighton Collaboration case definition per 100 000 doses of BNT162b2 administered by age group (12-15 years vs 16-17 years), sex, dose number, and interdose interval. All clinical information associated with symptoms, health care usage, diagnostic test results, and treatment at the time of the acute event were summarized. Results: There were approximately 1.65 million doses of BNT162b2 administered and 77 reports of myocarditis or pericarditis among those aged 12 to 17 years, which met the inclusion criteria during the study period. Of the 77 adolescents (mean [SD] age, 15.0 [1.7] years; 63 male individuals [81.8%]), 51 (66.2%) developed myocarditis or pericarditis after dose 2 of BNT162b2. Overall, 74 individuals (96.1%) with an event were assessed in the emergency department, and 34 (44.2%) were hospitalized (median [IQR] length of stay, 1 [1-2] day). The majority of adolescents (57 [74.0%]) were treated with nonsteroidal anti-inflammatory drugs only, and 11 (14.3%) required no treatment. The highest reported incidence was observed among male adolescents aged 16 to 17 years after dose 2 (15.7 per 100 000; 95% CI, 9.7-23.9). Among those aged 16 to 17 years, the reporting rate was highest in those with a short (ie, ≤30 days) interdose interval (21.3 per 100 000; 95% CI, 11.0-37.2). Conclusions and Relevance: Results of this cohort study suggest that there was variation in the reported incidence of myocarditis or pericarditis after BNT162b2 vaccine among adolescent age groups. However, the risk of these events after vaccination remains very rare and should be considered in relation to the benefits of COVID-19 vaccination.
No takes yet. Share an insight, caveat, or question.
Buchan et al. (2023) conducted a cohort in Myocarditis or pericarditis after COVID-19 BNT162b2 mRNA vaccination (n=77). BNT162b2 COVID-19 mRNA vaccine (dose 2 vs dose 1, and by age/sex/interdose interval) vs. Dose 1 recipients, longer interdose intervals (31-55 days or ≥56 days), and historical background expected incidence (2015-2019) was evaluated on Reported incidence of myocarditis or pericarditis meeting Brighton Collaboration case definition levels 1 to 3 per 100,000 doses of BNT162b2 administered (dose 2 vs dose 1 overall) (95% CI 4.7-8.3). BNT162b2 vaccination in adolescents aged 12-17 years was associated with a rare incidence of myocarditis/pericarditis, highest in males aged 16-17.
Synapse has enriched 10 related papers. Consider them for comparative context: